Literature DB >> 11244447

Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin.

U Platzbecker1, K Klingel, C Thiede, J Freiberg-Richter, D Schuh, G Ehninger, R Kandolf, M Bornhäuser.   

Abstract

A 17-year-old male with AML FAB M4 relapsed 4 months after myeloablative conditioning and peripheral blood stem cell transplantation (PBSCT) from an HLA-identical unrelated donor. A second PBSC harvest was infused 2 days after completion of cytoreductive therapy with mitoxantrone 7 mg/m(2)/day i.v. for 3 days (total dose 21 mg/m(2)), fludarabine 30 mg/m(2)/day i.v. for 6 days (total dose 180 mg/m(2)) and Ara-C 125 mg/m(2)/day i.v. for 5 days (total dose 625 mg/m(2)). Neutrophil recovery occurred on day +10 and was associated with GVHD grade III of the skin which was treated with cyclosporin A (CsA) and prednisone. Because of fever of unknown origin and progressive fatigue combined with hypotension on day +15 after second PBSCT, echocardiography was performed which revealed a dramatic decrease in systolic function compared to the status pre-transplant. On the same day acute heart failure with consecutive ventricular fibrillation occurred. Although resuscitation was performed immediately the patient died. The autopsy revealed massive infiltration by donor CD8-positive lymphocytes with concomitant extensive damage of the heart tissue. Acute myocarditis of viral origin was excluded by in situ hybridization and nested PCR techniques. In this patient, myocardial involvement by acute GVHD seems to have triggered a fatal arrhythmia and heart failure.

Entities:  

Mesh:

Year:  2001        PMID: 11244447     DOI: 10.1038/sj.bmt.1702744

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

Review 1.  Protein NMR in biomedical research.

Authors:  W Jahnke; H Widmer
Journal:  Cell Mol Life Sci       Date:  2004-02-26       Impact factor: 9.261

2.  Intrapericardial procedures for cardiac regeneration by stem cells: need for minimal invasive access (AttachLifter) to the normal pericardial cavity.

Authors:  H Rupp; T P Rupp; P Alter; N Jung; S Pankuweit; B Maisch
Journal:  Herz       Date:  2010-10       Impact factor: 1.443

3.  Pathological features of bone marrow transplantation-related toxicity in a mouse.

Authors:  Yong Hoon Kim; Chang Su Ha; Hyun Sook Lee; Sun Hwa Lim; Kyoung Sik Moon; Moon Koo Chung; Hwa Young Son
Journal:  J Vet Sci       Date:  2009-12       Impact factor: 1.672

4.  SMYD proteins in immunity: dawning of a new era.

Authors:  Maysaa Doughan; Nicholas Spellmon; Chunying Li; Zhe Yang
Journal:  AIMS Biophys       Date:  2016-10-17

5.  Extracorporeal life support survival in a pediatric hematopoietic cellular transplant recipient with presumed GvHD-related fulminant myocarditis.

Authors:  M S Zinter; B D Barrows; P C Ursell; K Kowalek; K Kalantar; N Cambronero; J L DeRisi; P Oishi; C C Dvorak
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

6.  Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation.

Authors:  Julie Charles; Diane Giovannini; Nicolas Terzi; Carole Schwebel; Nathalie Sturm; Dominique Masson; Marie-Thérèse Leccia; Jean-Yves Cahn; Olivier Manches; Claude-Eric Bulabois; Laurence Chaperot
Journal:  Exp Hematol Oncol       Date:  2019-03-28

Review 7.  Myocarditis with Advanced Atrioventricular Block after Allogeneic Stem Cell Transplantation: A Case Report and Literature Review.

Authors:  Masahiko Sumi; Mari Kitahara; Tsutomu Shishido; Hiroko Kazumoto; Nozomu Uematsu; Takehiko Kirihara; Keijiro Sato; Toshimitsu Ueki; Yuki Hiroshima; Kunihiko Shimizu; Hikaru Kobayashi
Journal:  Intern Med       Date:  2019-08-28       Impact factor: 1.271

8.  Polymyositis and myocarditis after donor lymphocyte infusion.

Authors:  Jae-Sook Ahn; Sang-Hee Cho; Yeo-Kyeoung Kim; Deok-Hwan Yang; Woo Kyun Bae; Hyun Jeong Shim; Je-Jung Lee; Ik-Joo Chung; Sang Woo Juhng; Hyeoung-Joon Kim
Journal:  Int J Hematol       Date:  2009-05-27       Impact factor: 2.319

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.